Morphological and molecular changes following neoadjuvant endocrine therapy of ER positive breast cancer: implications for clinical practice. by Badr, Nahla M et al.
(MRS NAHLA  BADR )Orcid ID : 0000-0003-1408-0227
Article type      : Original Article
Morphological and molecular changes following 
neoadjuvant endocrine therapy of ER positive breast 
cancer: implications for clinical practice
Nahla M. Badr 1 2, David Spooner3, Jane Steven3, Andrea Stevens3, Abeer M. Shaaban1 3
1Institute of Cancer and Genomic Sciences, The University of Birmingham, Edgbaston, Birmingham, UK,2 
Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Egypt. 3Queen Elizabeth 
Hospital, University Hospitals Birmingham, Birmingham, UK
Corresponding authors
Dr Abeer M Shaaban
Queen Elizabeth Hospital Birmingham and University of Birmingham
Mindelsohn Way, Edgbaston
Birmingham B15 2GW
Tel:  + (44) 1213713356









This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/HIS.14331
 This article is protected by copyright. All rights reserved
This article is protected by copyright. All rights reserved
Email:  abeer.shaaban@uhb.nhs.uk
              a.shaaban@bham.ac.uk
Disclosure of funding:











This article is protected by copyright. All rights reserved
Abstract
Background: Neoadjuvant endocrine therapy (NAET) is used in the management of estrogen 
receptor positive (ER+) breast cancer. The optimal method for histological assessment of response 
and the effect of NAET on the tumour morphology, grade and molecular profile remain unclear. 
Material and methods:  A single large institution cohort of 132 patients who received NAET 
over a 13-year period was identified. Comprehensive clinical, histopathological and follow up data 
were collected. A detailed histological review of a subset with residual post-treatment carcinoma 
was undertaken. 
Results: Two carcinomas (both of lobular type) achieved complete pathological response. Central 
scarring was seen in 49.3% of tumours post-treatment. Significant changes in tumour type 
(41.6%), grade (downgrading in a third of tumours), PR expression (22.3%) with a switch to PR 
negative status in 17.6% of cases were observed. The latter was associated with absence of tumour 
infiltrating lymphocytes (p=0.005).  10% of cases showed a change in HER2 expression 
(p=0.002). Median patient survival was 60 months and downgrading of tumours was associated 
with better overall survival (p=0.05).
Conclusions: We propose a histological method for assessment of residual carcinoma following 
NAET and recommend repeat ER/PR/HER2 testing to inform management and prognosis.
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PEPI: Pre-operative Endocrine Prognostic Index 
PR: Progesterone Receptor
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Introduction
Endocrine therapy is increasingly being used upfront for the treatment of breast cancer  either as 
primary therapy for patients unsuitable for chemotherapy/surgery  (1), (2) or as a neoadjuvant 
treatment option for hormone receptor positive breast cancer. Neoadjuvant endocrine therapy 
(NAET) can reduce tumour size to allow breast conservation and also influence the management 
decision on chemotherapy (3). Patients with hormone receptor positive breast cancer showed 
overall clinical response rates ranging from 36-51% for tamoxifen and 38-70% for aromatase 
inhibitors (AIs) (4-11). A UK multicenter audit of neoadjuvant therapies showed considerable 
variation in the uptake rate and practice of NAET with patchy information on the pathological 
response rate (12). During the COVID pandemic, patients with ER positive HER2 negative early 
breast cancer received neoadjuvant endocrine therapy to postpone surgical treatment that was 
prioritized for the more urgent and aggressive tumours such as triple negative and HER2 positive 
cancers (13, 14). Therefore, it has become essential for pathologists and the multidisciplinary teams 
to be familiar with the handling, reporting and management of patients undergoing NAET. 
Currently, the pre-operative endocrine prognostic index (PEPI) is the only available index that 
relates the response to therapy and risk of relapse but is not currently in use in routine practice. It 
is based on the assessment of tumour size, nodal status, Ki67 level and ER Allred score. Patients 
with low pathological stage and a favorable biomarker profile (PEPI score 0) showed a lower rate 
of relapse indicating that adjuvant chemotherapy can be omitted compared with those with high 
pathological stage disease at surgery and a poor biomarker profile (3). There is sparsity of data on 
the histological changes that follow NAET regarding tumour profile and hormonal receptor 
expression. Unlike neoadjuvant chemotherapy, there are no guidelines to assess pathological 
response after NAET and neoadjuvant chemotherapy reporting systems are not validated for use in 
the endocrine setting. Therefore, there is inconsistency of assessment and histological reporting of 
post-neoadjuvant endocrine tumours (15). In this study, we aim to investigate the NAET effect on 
tumour type, grade, and molecular profile through analyzing a well characterized cohort of tumour 
samples in a single large UK tertiary referral center and provide guidance on the pathological 
assessment of those lesions to inform adjuvant management and prognosis. 
Patients and methods
Female patients who underwent NAET for invasive breast carcinoma at Queen Elizabeth Hospital 
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Included in this study were patients with primary ER positive operable breast carcinoma who 
received NAET followed by breast surgery in the period between November 2007 and December 
2019. The treatment was standardised as per the national and local protocols and the average 
duration of treatment was 6 months. Patients who did not undergo surgery (primary endocrine 
therapy) were excluded. Surgical specimens were sampled thoroughly similar to the neoadjuvant 
chemotherapy specimen sampling. Where possible, a marker clip was inserted before therapy to 
indicate the site of the tumour. Where no tumour could be identified macroscopically, specimen x-
raying was performed to identify a marker clip, radiological calcification and/or residual tumour.
Data collection
Comprehensive clinical data including patients’ age, ethnicity, type of NAET treatment, type of 
surgery and overall survival (OS) data were collected.  The following pathological data, where 
available, were identified from the pathology reports on both pre-treatment core biopsy samples 
and residual tumours: tumour type, tumour grade including individual scores for tubule formation, 
nuclear pleomorphism and mitoses, estrogen (ER) and progesterone receptor (PR) status, HER2 
status and pathological response. Immunohistochemistry score of 3+ or 2+   fluorescence in situ 
hybridization (FISH) amplified were defined as HER2 positive as per the UK guidelines (16). The 
response was classified into pathological complete response (pCR) (no residual invasive 
carcinoma in breast and axillary nodes), minimal residual disease (≤ 10% residual invasive 
carcinoma), pathological partial response (residual invasive carcinoma comprising >10% with 
histological evidence of tumour response), and no response (no evidence of tumour response). A 
detailed histological review of tumour morphology, grade, tumour cellularity (assessment of 
percentage of average cancer cellularity across the largest cross section of the residual tumor bed), 
scarring pattern (central versus diffuse fibrosis) with central scarring defined as central acellular 
fibrous area  surrounded by residual tumour cells (15), margin status (pushing vs infiltrating), 
architecture of the tumour (nodular vs diffuse) was undertaken on 75 of post-operative tumour 
sections by two pathologists (NMB, AMS), including a specialist breast pathologist. Tumour 
infiltrating lymphocytes (TILs) were also assessed in the residual post treatment carcinoma 
following the International Immuno-Oncology Biomarker Working Group on Breast Cancer 
guidelines. Stromal TILs (TILs that were not in direct contact with the tumour nests or cells) were 
evaluated. Immune infiltrates outside of the tumour borders, e.g.in adjacent normal tissue or DCIS 










This article is protected by copyright. All rights reserved
Immunohistochemical staining was performed for the characteristic areas of tumours from 
microscopically selected samples (regions), based on examining the standard (hematoxylin and 
eosin) H&E staining. De waxing of the slides in PT link DAKO automated immunohistochemistry 
system is processed for hormonal receptors and in Roche Ventana Ultra machine for HER2 
staining. The slides were processed in target retrieval solution for 70 minutes at 97 C (Cell 
Conditioning solution 1(CC1) for 64 minutes at 95 C in HER2 staining). CC1 next blocking step 
was performed using peroxidase inhibiter preceded and followed by washing. The slides were 
incubated in the primary antibody (ER; clone EP1, DAKO, RTU, PR; clone PgR 1294, DAKO, 
RTU and HER2; clone 4D5. After wash, slides were incubated in FLEX/HRP for 30 minutes 
blocking step and FLEX DAB for 10 minutes, each with a wash before and after (in HER2 
staining, HRP multi timer was used instead for 8 minutes blocking step (Roche, antibody diluent 
with casein) and DAB was added for 8 minutes with wash before and after that followed by 
copper sulphate solution for 4 minutes). Lastly embedding the slides into Hematoxylin was done 
for 15 minutes.
Statistical analysis
Statistical analysis was done using the IBM SPSS package V.24. Analysis for pre- and post-
treatment categorical variables including tumour type, grade, ER/PR Allred score and HER2 
expression was done using Chi-square test.  Receptor status was also dichotomised into negative 
and positive using a cut-off value of Allred score >2 for ER/ PR and Her2 immunohistochemical 
score of 3+ (or 2+ fluorescence in situ hybridization (FISH) positive) to define positivity. The 
non-parametric Kruskal Wallis test was used to assess the relation between cellularity as a 
continuous variable and response to therapy. The Kaplan-Meier method was used for survival 
analysis. Overall survival was defined as the duration in months between the date of diagnosis and 
the date of last follow-up or death. A p-value of ≤0.05 was considered significant.
Results 
A total of 132 patients fulfilled the inclusion criteria. The neoadjuvant regimen was predominantly 
aromatase inhibitors (AIs, 96.2%) with the rest of patients receiving Tamoxifen. The pre-treatment 
clinicopathological characteristics of all patients are summarised in table 1.  The majority (96.2 %) 
of the patients were aged over 50 with a median age of 73 years (range: 40 - 93 years) and were 
mostly Caucasian (84.1%). On pre-treatment biopsy, the tumours were predominantly of no 
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positive; of which 88.6% were PR positive and 6.8% HER2 positive. The few HER2 positive 
patients were administered neoadjuvant endocrine therapy and not chemotherapy or anti- HER2 
therapy either due to age/comorbidities or patient choice. Pathological complete response (pCR) 
was achieved in two cases (2.6%) while 18.2%, 75.3% and 3.9% of patients showed minimal 
residual disease, pathological partial response, and no pathological response, respectively. The two 
cases that achieved pCR were of patients of Caucasian ethnicity; aged 74 and 58 years. Both were 
diagnosed with invasive classical lobular carcinoma of grade 2, hormone receptor strongly 
positive (Allred scores for ER were 8/8 for both, PR scores were 6/8 and 7/8, respectively) with 
negative HER2 status. 
Of note, tumours that received AIs were statistically significantly more likely to show histological 
evidence of tumour response compared with the Tamoxifen group (97.2% vs 75%, p=0.03). 
Tumour stage 2 (ypT2) was seen in 64.8% of the patients. Breast conserving surgery was achieved 
in 67.4% of patients. Sentinel lymph node biopsy was performed in 68.8% with nodal metastasis 
observed in 49.6% of patients.
Histological tumour type
The two invasive carcinomas that showed pCR were of the lobular type. There was a change in the 
histological type following NAET in 55 out of 132 cases (41.6%) and this was statistically highly 
significant (p=0.001) with an increase in tubular carcinoma by 3% and a decrease in the mixed 
subtypes by 1.5%. Details of the histological types before and after NAET are shown in table 2.
Tumour grade
Table 3 summarises tumour grades pre- and post-NAET. Downgrading (decrease in the overall 
grade by at least one grade) was observed in 30.4 % of cases, and up-grading (increase in overall 
grade by at least one grade) in 15.6% (p=0.01).  The downgrading was predominantly due to a 
decrease in the mitotic count (p<0.001) and an increase in tubule formation (p= 0.05) and was 
significantly associated with better survival. Grade 2 and 3 tumours comprised 85.9% of cases on 
pre-treatment core biopsies. This proportion decreased to 69.5% following treatment. The 
proportion of grade 1 carcinoma increased from 14% to 30.4% post-NAET.
Histological features of response to NAET
Of the 75 available post-treatment surgical excisions, 77.3% showed infiltrative tumour margins. 
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with an average of 40.6%. Lymphocytic infiltration was noted in 25.3% of cases. A nodular 
architecture of the tumour comprising multiple adjacent foci was noticed in 32% of cases (Table 
4). Reduced tumour cellularity was significantly related to achieving response to therapy 
(p<0.001) (Fig. 1b, 1c). 
ER expression
Following treatment, one out of 130 available tumour pairs (0.7%) changed profile from ER 
positive to negative. Five cases (Allred scores 6 and 7) showed an increase in Allred score by at 
least one score. Ten cases (Allred score 8) showed reduced ER expression by at least one score.
PR expression 
The PR status showed a highly significant change between pre- and post-treatment tumour 
samples in 22.3% of cases (p <0.001). Twenty-three cases (17.6%) changed from PR positive to 
negative status (Fig.1d, 1e) and five changed from negative to positive (3.8%). Further variation in 
the Allred score without affecting the final PR status was noted in sixty-nine cases (52.2%) (table 
5). Tumours that retained the same PR status following therapy correlated with better response to 
therapy (p=0.018). Decrease of PR Allred score was significantly associated with absence of 
lymphocytic infiltration (p=0.005). 
HER2 expression
One hundred and fourteen HER2 negative (87.7%) and another three HER2 positive (2.3%) 
tumours retained the same profile following NAET treatment. A discordant HER2 status following 
treatment was noted in 13 out of 130 cases (10%). Five cases changed profile from HER2 
overexpression to HER2 negative (3.8%). Eight cases changed from negative to positive status 
following treatment (6.1%). This change was statistically highly significant (p = 0.002).
Lymph node response
Pre-treatment lymph nodes were assessed by imaging and cytology/biopsy sampling. Following 
NAET, 49.6% of tumours showed histologically confirmed nodal metastasis. The nodal metastasis 
showed similar histological features of regression to the breast carcinoma particularly the 
associated fibrosis. No significant association between nodal status and the patient outcome was 
found in this cohort. 
Patient survival 
Overall survival ranged from eight to 137 months with a median of 60 months (Inter quartile range 
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better overall patient survival (p=0.05). Patients with no change in their PR status following 
NAET had longer mean survival time than those whose tumours that lost PR expression following 
treatment (107.3 months and 91.7 months) respectively. However, this difference did not reach 
statistical significance.  No significant association was found between other histological 
parameters and patient overall survival. 
Discussion
Little is known about the effect of neoadjuvant endocrine therapy (NAET) on breast tumour 
characteristics. In this study, we report significant changes in the histological tumour type, grade, 
cellularity, and receptor status following NAET. We show that tumours tended to acquire more 
specialized phenotypes with a change of 21/84 of NST carcinomas (25%) to other special tumour 
types including tubular, lobular, mucinous and/or mixed types. Downgrading of invasive 
carcinoma was associated with better overall survival.
The variation in the histological type, grade, hormone receptor and HER2 status is intriguing. 
While this may reflect a genuine change in the tumour phenotype as a result of neoadjuvant 
endocrine therapy, the effects of sampling and/or tumour heterogeneity should also be considered. 
For example, the change of 8 lobular carcinomas and 3 mucinous carcinomas into no special type 
carcinoma is likely to reflect a pre- treatment mixed phenotype and/or tumour heterogeneity. It is 
plausible that the limited core biopsy sampled a different histological type/profile to the full 
excision. It is also possible that various tumour profiles responded differently to NAET with the 
least responsible/resistant phenotype remaining as residual carcinoma. We therefore recommend 
repeat testing of the residual carcinoma for ER/PR/HER2 as a switch from negative to positive 
result would provide treatment options for patients. The final molecular profile may be a better 
indicator of prognosis compared with the pre-treatment sample. In the current study, tumours that 
retained their PR profile were associated with better survival. A change in PR status from positive 
to negative may be an early indication of endocrine resistance. 
NAET has an anti-proliferative effect on breast tumour cells, which is associated with reduced 
expression of the proliferation marker Ki67 in patients showing response to therapy irrespective of 
NAET regimen (18-20).  A previous study reported downgrading of the breast carcinomas following 
either AIs or tamoxifen. This was associated with fewer mitoses with AI therapy while tamoxifen  
induced more tubule formation (18). Here, we report a significant reduction of the mitotic activity 
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following AIs. In addition, complete pathological response of two invasive lobular carcinomas 
was achieved. In the UK, Ki67 is not performed routinely on breast carcinomas with and without 
prior therapy as per the NHS Breast Screening Programme (NHSBSP) guidelines (21)
 In the current study, a minor effect of NAET on ER expression was noted with only one case 
switching to an ER negative status. The effect of NAET on ER expression had not been well 
documented in the literature and the data so far has been conflicting with reports suggesting a 
reduction (19) (20) or no significant effect following neoadjuvant AIs (22).
Data from the IMPACT trial showed a reduction in PR levels by 41% and 82% at 2 and 12 weeks 
of anastrazole therapy respectively while tamoxifen resulted in its increased expression at 2 weeks 
followed by a return to pre-treatment levels at 12 weeks (22). A reduction in PR expression levels 
following NAET has also been documented in previous studies (18, 23). It has long been thought that 
PR positivity is a pre-requisite for a favourable response to endocrine therapy (24).  Progesterone 
receptor status significantly improved outcome prediction over estrogen receptor status alone for 
adjuvant endocrine therapy in two large breast cancer databases (24) and is considered an indication 
of an intact ER signaling pathway (25, 26). Subsequently, PR was shown to be downregulated by 
growth factors indicating it is a potential surrogate for breast cancer tumour activity (25). The 
IMPACT trial showed more marked reduction of ki67 levels in the PR positive tumours (22). Our 
reported decrease in PR levels in 69.8% of cases following treatment may be an indication of 
suppression of the ER signaling pathway and less likelihood for further tumour response to 
endocrine therapy compared with tumours that retain PR expression. Although there was no 
correlation between this change and overall patient survival, we observed that patients with no 
change in their tumour PR status had longer mean survival time than those that lost PR expression 
following NAET. This might be a reflection of the poor prognostic effect of loss of PR expression 
following NAET.  
The change in HER2 expression following neoadjuvant endocrine therapy is a novel finding. A 
cross talk between the ER and HER2 pathways has been described (27) and a change in 
ER/PR/HER2 expression following neoadjuvant chemotherapy has been well documented (28, 29). 
The precise mechanisms by which residual tumours change profile remain unknown. A recent 
concept of transcriptional plasticity/adaptation to allow tumour cells to escape the treatment 
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both at the mRNA and protein levels (31). ER was also shown to stimulate down-regulation of the 
HER1 and HER2 expression (32, 33). Thus, a combination of the AIs and trastuzumab correlated 
with a longer progression-free survival compared with AIs alone in the HER2 positive tumours 
(34). In the neoadjuvant setting, potent anti-HER2 treatment with trastuzumab and lapatinib 
combined with letrozole in patients with locally advanced HER2 positive/ ER positive breast 
carcinoma resulted in pCR rate of 21% (35). A long follow up for those patients that showed a 
change in tumour profile is warranted to confirm the clinical significance of this finding.
The rate of pCR reported in this study is remarkably low. pCR in the neoadjuvant endocrine 
setting  has uniformly been reported to be less than 10% and this was confirmed in a recent meta-
analysis (36). Morphological changes of tumour regression were evident following NAET and 
included decreased tumour cellularity and increased fibrosis (15, 18). In this current study, central 
fibrous scarring was a frequent finding, identified in almost half of the cases. Thomas et al., were 
first to document the appearance of central scarring in 58.5% of their cohort treated with hormonal 
therapy as compared with systemic chemotherapy (4%). In their study, central scarring was 
associated with clinical reduction of tumour volume (15). We did not find a correlation between 
central scarring and the pathological response to therapy or patient survival. 
Although lymphocytic infiltration was not a common feature following NAET, we observed that 
the absence of lymphocytic infiltrate was significantly related to decreased PR expression in post-
treatment samples. This highlights a potential link between the tumour immune response and PR 
suggesting a prognostic role for TILs in the neoadjuvant endocrine setting.  Infiltrating immune 
cells in pre-treatment cores were shown to be associated with poor response to neoadjuvant AIs. 
(37).
Downgrading of tumours correlated with longer patient overall survival. However, no significant 
correlation was found between other studied clinical or histological parameters and survival in our 
cohort. As per a comprehensive meta-analysis of neoadjuvant studies, correlation with survival as 
an end point for NAET studies may be challenging.  Possible reasons include the recommended 
use of adjuvant endocrine therapy with variable adherence, potential use of adjuvant 
chemotherapy, and the long indolent course of the ER positive tumours and their low early 
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There are some similarities and differences in the histological response following NACT and 
NAET. While some histological feature, such as fibrosis, decreased cellularity and lymphocytic 
infiltrate are common to both neoadjuvant chemotherapy and neoadjuvant endocrine response, we 
confirmed that central scarring was characteristic of NAET response and is seen in approximately 
half of the cases while this feature is uncommon following NACT. This observation was first 
reported by Thomas et al 2008 (15) and confirmed in this study. The changes in tumour 
morphology, grade, ER/PR/HER2 status have previously been reported following NACT in 
several studies. However, the proportion of carcinomas showing ER conversion (from positive to 
negative) following NACT (5.7%(38),  12.4%(39),  5.2%(28))  is much higher than that noted after 
NAET in the current  study (one case, 0.77%) .
In conclusion, we report significant changes in tumour morphology, PR and HER2 expression 
following neoadjuvant endocrine therapy. Downgrading of invasive carcinomas post-treatment is 
associated with better survival. Central fibrous scarring is a common finding and lymphocytic 
infiltration seems to play a role in association with the decreased PR expression following therapy. 
The data highlight the importance of thorough histological assessment of the post-treatment 
surgical specimens. We recommend detailed pathological examination of the residual post-NAET 
tumours including tumour grade, presence/absence of central scarring, lymphocytic infiltrate, and 
repeat hormone receptor and HER2 testing (table 6). The changes in hormone receptor and HER2 
status may be prognostic and predictive of response to therapies that otherwise would not be 
offered to patients based on the pre-treatment tumour profile. Standardized reporting of those 
increasingly encountered complex specimens is required to allow comparison of results among 
institutions globally and to help collect high quality histological and outcome data to inform future 
patient management.
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No special type (NST) 84 (63.6%)
Lobular carcinoma 22 (16.7%)
Other (mucinous, tubular) carcinoma 9 (6.8%)






























Aromatase inhibitors 127 (96.2%)
Tamoxifen 5 (3.8%)
Type of surgery
Breast conserving surgery 89 (67.4%)
Mastectomy 43 (32.6%)









This article is protected by copyright. All rights reserved
**Tumour size was assessed radiologically before treatment (data for 10 cases were not 
available)
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Table 2
Details of tumour type pre and post-neoadjuvant endocrine therapy
NAET: Neoadjuvant endocrine therapy
NST: No special type carcinoma

















63 4 3 6 8 0 84
Lobular 
carcinoma
8 10 0 0 2 2 22
Mucinous 
carcinoma
3 1 1 0 1 0 6
Tubular 
carcinoma
1 1 0 0 1 0 3
Mixed 
carcinoma
11 2 0 1 3 0 17
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Table 3 





I 11 6 1 18
II 27 54 13 94
III 1 11 4 16
Total 39 71 18 128*
NAET: Neoadjuvant endocrine therapy
*Two specimens had no residual disease and grading was not applicable in further two due to the 
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Table 4















Pathological complete response (pCR) 2(2.6%)
Minimal residual disease 14(18.2%)
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Table 5
PR Allred score pre- and post-neoadjuvant endocrine treatment
PR post-NAETPR pre-
NAET
0 1 3 4 5 6 7 8 NA
Total
0 10 0 0 1 1 1 0 1 0 14
2 0 0 1 0 0 0 0 0 0 1
3 0 0 2 0 0 0 0 1 0 3
4 1 0 0 2 0 2 0 0 0 5
5 3 0 0 1 6 1 0 1 0 12
6 1 0 1 2 1 1 1 1 1 9
7 5 0 1 2 1 1 1 0 1 12
8 13 1 7 5 11 8 4 27 0 76
Total 33 1 12 13 20 14 6 31 2 132
PR: Progesterone receptor, NAET: Neoadjuvant endocrine therapy.
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Table 6: Recommended microscopic features to include in the histological reporting of post-




Tumour margin:  pushing/infiltrative
Central scarring: present/absent
Tumour cellularity: (%)






Pathological complete response (pCR)
Minimal residual disease: (≤ 10% residual invasive carcinoma with evidence of tumour response)
Partial response (PR): (>10% residual invasive carcinoma with evidence of tumour response)










This article is protected by copyright. All rights reserved
Figure legends
Figure 1: Histological features of response to neoadjuvant endocrine therapy  
1a. Post-treatment surgical excision showing central fibrous scarring with peripheral viable tumour 
cells.
1b. High tumour cellularity pre-treatment.
1c. Low tumour cellularity post-treatment, same tumour. 
1d. PR positive invasive no special type carcinoma (pre-treatment).
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